Finch Therapeutics
200 Inner Belt Road
Suite 400
Somerville
Massachusetts
02143
United States
Website: http://finchtherapeutics.com
Email: info@finchtherapeutics.com
About Finch Therapeutics
Finch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Through this and other clinical datasets, Finch identifies the microbes that drive desirable clinical outcomes, and develops therapies that deliver those microbial communities to patients. FIN-403 is both Finch’s lead clinical program and a valuable tool for its broader human-first discovery strategy.YEAR FOUNDED:
2014
LEADERSHIP:
CEO: Mark Smith
COO: Andrew Noh
CFO: Susan Clancy
JOBS:
Please click here for Finch job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
55 articles with Finch Therapeutics
-
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
-
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/16/2022
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
-
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
5/9/2022
Finch Therapeutics Group, Inc. today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.
-
ImmunoGen, which is developing Antibody-drug conjugates (ADCs) for the treatment of cancer, is on a hiring spree. The company is looking to hire for more than 200 positions by the end of 2022.
-
A roundup of last week's top clinical trial updates and news.
-
Finch Therapeutics has been given the green light to continue the Phase III Prism4 clinical trial, investigating the efficacy of CP101 in fighting recurrent C. difficile infections (CDI).
-
Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND
4/28/2022
Finch Therapeutics Group, Inc. announced that the U.S. Food and Drug Administration has removed the clinical hold on Finch’s investigational new drug application for CP101.
-
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
4/19/2022
Finch Therapeutics Group, Inc. today announced plans to reduce its workforce by approximately 20%.
-
Finch Therapeutics has slashed its headcount by 20% in order to free funds to focus its resources on its programs in recurrent C. difficile infection and autism spectrum disorder
-
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
3/31/2022
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, reported fourth quarter and full year 2021 financial results and provided business updates.
-
The FDA asked Finch to pause enrollment for the trial on CP101 in recurrent C. difficile infection, pending details on how SARS-CoV-2 donor samples will be shipped to the vendor.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Finch Therapeutics Announces Additions to Senior Leadership Team
2/10/2022
Finch Therapeutics Group, Inc. today announced the appointment of Bryan Gillis, MBA, to Chief Technology Officer, Alka Batycky, PhD, to Chief Development Officer, and Howard Franklin, MD, MBA, to Senior Vice President, Late-Stage Development and Gastrointestinal (GI) Therapeutic Area Lead.
-
Bayer isn't the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
-
Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
1/4/2022
Finch Therapeutics Group, Inc. today announced that Mark Smith, PhD, Chief Executive Officer, will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 a.m.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
BioSpace Movers & Shakers, Nov. 12
11/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Finch Therapeutics to Participate in Upcoming Investor Conferences
11/11/2021
Finch Therapeutics Group, Inc. today announced that Mark Smith, PhD, Chief Executive Officer, will participate virtually in two upcoming investor conferences: Jefferies London Healthcare Conference
-
Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
11/10/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, reported financial results for the third quarter ended September 30, 2021 and provided business updates.
-
Finch Therapeutics Announces Transition of Chief Medical Officer
11/10/2021
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Zain Kassam, MD, MPH has elected to step down as Chief Medical Officer in order to return to Canada to attend to a family health matter.